NeuBase Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
Sep. 30, 2016
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 7 – NOTES PAYABLE On February 28, 2016, the Company entered into a premium financing arrangement for its directors’ and officers’ insurance policy in the amount of $215,810. The financing arrangement bears interest at 7.0% per annum and will be fully paid in ten months from the date of issuance. As of September 30, 2016, the Company had repaid $128,012 of principal and had paid interest of $5,664. On February 28, 2015, the Company entered into a premium financing arrangement for its directors and officers insurance in the amount of $212,400. The financing arrangement bears interest at 6.75% and will be fully paid in nine months from the date of issuance. As of September 30, 2016, the Company had repaid $212,400 of principal and had paid interest of $5,950.

NOTES PAYABLE

12 Months Ended

Sep. 30, 2016

NOTE 7 – NOTES PAYABLE

On February 28, 2016, the Company entered into a premium financing arrangement for its directors’ and officers’ insurance policy in the amount of $215,810. The financing arrangement bears interest at 7.0% per annum and will be fully paid in ten months from the date of issuance. As of September 30, 2016, the Company had repaid $128,012 of principal and had paid interest of $5,664.

On February 28, 2015, the Company entered into a premium financing arrangement for its directors and officers insurance in the amount of $212,400. The financing arrangement bears interest at 6.75% and will be fully paid in nine months from the date of issuance. As of September 30, 2016, the Company had repaid $212,400 of principal and had paid interest of $5,950.